JP2016506908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506908A5 JP2016506908A5 JP2015552819A JP2015552819A JP2016506908A5 JP 2016506908 A5 JP2016506908 A5 JP 2016506908A5 JP 2015552819 A JP2015552819 A JP 2015552819A JP 2015552819 A JP2015552819 A JP 2015552819A JP 2016506908 A5 JP2016506908 A5 JP 2016506908A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- composition according
- albumin
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710113436 GTPase KRas Proteins 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 15
- 102000009027 Albumins Human genes 0.000 claims description 12
- 108010088751 Albumins Proteins 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- 229940123237 Taxane Drugs 0.000 claims description 10
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 10
- 102200007373 rs17851045 Human genes 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 102200006657 rs104894228 Human genes 0.000 claims description 4
- 102200006532 rs112445441 Human genes 0.000 claims description 4
- 102200006520 rs121913240 Human genes 0.000 claims description 4
- 102200006531 rs121913529 Human genes 0.000 claims description 4
- 102200006537 rs121913529 Human genes 0.000 claims description 4
- 102200006539 rs121913529 Human genes 0.000 claims description 4
- 102200006538 rs121913530 Human genes 0.000 claims description 4
- 102200006540 rs121913530 Human genes 0.000 claims description 4
- 102200006541 rs121913530 Human genes 0.000 claims description 4
- 102220197834 rs121913535 Human genes 0.000 claims description 4
- 102200006648 rs28933406 Human genes 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102220014333 rs112445441 Human genes 0.000 claims description 3
- 102200006533 rs121913535 Human genes 0.000 claims description 3
- 102220640055 Alpha-mannosidase 2_G12L_mutation Human genes 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102220530637 Putative apolipoprotein(a)-like protein 2_G12F_mutation Human genes 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 102200006562 rs104894231 Human genes 0.000 claims description 2
- 102220197831 rs121913527 Human genes 0.000 claims description 2
- 102200006564 rs121917759 Human genes 0.000 claims description 2
- 102220334606 rs1348427922 Human genes 0.000 claims description 2
- 102220293980 rs143960528 Human genes 0.000 claims description 2
- 102200007376 rs770248150 Human genes 0.000 claims description 2
- 230000000869 mutational effect Effects 0.000 claims 1
- 102220197833 rs112445441 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 102200006525 rs121913240 Human genes 0.000 description 3
- 102220197780 rs121434596 Human genes 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US61/848,793 | 2013-01-11 | ||
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US61/752,417 | 2013-01-14 | ||
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| US13/794,712 | 2013-03-11 | ||
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506908A JP2016506908A (ja) | 2016-03-07 |
| JP2016506908A5 true JP2016506908A5 (enExample) | 2017-02-16 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552819A Pending JP2016506908A (ja) | 2013-01-11 | 2014-01-10 | Ｋ−ｒａｓの変異状態に基づくがんの処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (enExample) |
| EP (1) | EP2943184A4 (enExample) |
| JP (1) | JP2016506908A (enExample) |
| KR (1) | KR20150103746A (enExample) |
| AU (1) | AU2014205254A1 (enExample) |
| BR (1) | BR112015016466A2 (enExample) |
| CA (1) | CA2897581A1 (enExample) |
| HK (1) | HK1217292A1 (enExample) |
| IL (1) | IL239740A0 (enExample) |
| MX (1) | MX2015008889A (enExample) |
| WO (1) | WO2014110408A1 (enExample) |
| ZA (1) | ZA201504878B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| NZ595313A (en) | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| CA2880727C (en) | 2005-08-31 | 2019-05-07 | Neil P. Desai | Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| WO2008021288A2 (en) | 2006-08-11 | 2008-02-21 | Johns Hopkins University | Consensus coding sequences of human breast and colorectal cancers |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| PT2419732T (pt) | 2009-04-15 | 2019-12-24 | Abraxis Bioscience Llc | Composições e métodos de nanopartículas isentas de priões |
| PL2552438T3 (pl) | 2010-03-26 | 2016-12-30 | Sposoby leczenia raka wątrobowokomórkowego | |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| JP6257324B2 (ja) | 2010-06-04 | 2018-01-10 | アブラクシス バイオサイエンス， エルエルシー | 膵臓がんの処置方法 |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| SMT201900502T1 (it) | 2011-12-14 | 2019-11-13 | Abraxis Bioscience Llc | Uso di eccipienti polimerici per la liofilizzazione o il congelamento di particelle |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| BR112016013138A2 (pt) | 2013-12-09 | 2018-01-16 | Targovax Asa | mistura de peptídeos |
| WO2015169804A1 (en) * | 2014-05-06 | 2015-11-12 | Targovax As | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| JP6987644B2 (ja) | 2015-06-29 | 2022-01-05 | アブラクシス バイオサイエンス， エルエルシー | 類上皮細胞腫瘍を処置する方法 |
| AU2017340913A1 (en) * | 2016-10-07 | 2019-04-18 | Abraxis Bioscience, Llc | Methods of treating biliary tract cancer |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| US20230172935A1 (en) * | 2020-05-08 | 2023-06-08 | Cardiff Oncology, Inc. | Methods of monitoring kras mutations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595313A (en) * | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| EP1913157B2 (en) * | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| MX2009009787A (es) * | 2007-03-13 | 2009-09-22 | Amgen Inc | Mutaciones de k-ras y terapia con anticuerpos anti-egfr. |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| CN102573832B (zh) * | 2009-08-25 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗 |
| RU2016119999A (ru) * | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| KR20130043104A (ko) * | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| WO2011146803A1 (en) * | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| EP3444363B1 (en) * | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CA2865335A1 (en) * | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| WO2013138371A1 (en) * | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506908A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| JP2016513097A5 (enExample) | ||
| JP2016512513A5 (enExample) | ||
| JP2016512506A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| NZ630392A (en) | Methods of treating lung cancer | |
| JP2013523656A5 (enExample) | ||
| JP2013527232A5 (enExample) | ||
| JP2015536950A5 (enExample) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2017008088A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| RU2021128415A (ru) | Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения | |
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2019526543A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| JP2016513657A5 (enExample) | ||
| BRPI0606283A2 (pt) | formulações de antagonista de receptor de leucotrieno/corticosteróide em nanopartìcula | |
| Wang et al. | A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002) | |
| JP2015502926A5 (enExample) | ||
| WO2016142708A3 (en) | Pharmaceutical composition | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same | |
| HK1259083A1 (zh) | 用於治疗系统性肥大细胞增多症的方法和组合物 |